Eczema Trials: Quality of Life Instruments Used and Their Relation to Patient-reported Outcomes. A Systematic Review

Heinl, Daniel; Chalmers, Joanne R; Nankervis, Helen; Apfelbacher, Christian

doi:10.2340/00015555-2322

Cited by 30 publications

(32 citation statements)

References 205 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The strengths of this study include the following: it was a large‐scale population‐based study with a diverse sample and sample weights that adjusted for multiple sociodemographics and allowed for generalization of results that are representative of the U.S. population; it used multiple and well‐validated assessments of AD severity and controlled for multiple confounding variables in multivariable models. POEM, PO‐SCORAD and self‐reported global AD severity have all been studied in patients with AD and are considered to have good overall face validity, construct validity, internal consistency, reliability and/or responsiveness; POEM is the preferred assessment of AD symptoms for clinical trials by the Harmonising Outcome Measures in Eczema group . There is some debate regarding the optimal cut‐off to use for a case definition of anxiety or depression.…”

Section: Discussionmentioning

confidence: 99%

Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults

et al. 2019

View full text Add to dashboard Cite

SummaryBackgroundThe relationship between atopic dermatitis (AD), anxiety and depression in the U.S. adult population is not well established.ObjectivesTo determine the relationship of AD and its severity with symptoms and diagnosis of anxiety and depression in U.S. adults.MethodsA cross‐sectional, population‐based study of 2893 adults was performed. AD was determined using modified U.K. Diagnostic Criteria.ResultsAdults with AD vs. those without AD had higher mean Hospital Anxiety and Depression Scale anxiety (HADS‐A) (7·7 vs. 5·6) and depression (HADS‐D) (6·0 vs. 4·3) scores and higher prevalences of abnormal (≥ 11) HADS‐A (28·6% vs. 15·5%) and HADS‐D (13·5% vs. 9·0%) scores. In multivariable linear and logistic regression models controlling for sociodemographics, AD was associated with significantly higher mean HADS‐A and HADS‐D scores (7·7 and 6·0) and higher odds of abnormal HADS‐A [odds ratio (OR) 2·19, 95% confidence interval (CI) 1·65–2·91] and HADS‐D scores (OR 1·50, 95% CI 1·04–2·17) (P ≤ 0·03 for all). Mean and abnormal HADS‐A and HADS‐D scores were increased in moderate and severe/very severe self‐reported global AD severity, Patient‐Oriented Eczema Measure (POEM), Patient‐Oriented Scoring AD (PO‐SCORAD), PO‐SCORAD itch and sleep (P < 0·0001 for all). All respondents with severe PO‐SCORAD, POEM and PO‐SCORAD itch had borderline or abnormal HADS‐A and HADS‐D scores. Adults with AD vs. those without AD had higher prevalence of self‐reported healthcare‐diagnosed anxiety or depression in the past year (40·0% vs. 17·5%). Many adults with AD who had borderline and/or abnormal HADS‐A or HADS‐D scores reported no diagnosis of anxiety or depression.Conclusions AD is associated with significantly increased anxiety and depression, which may go undiagnosed. What's already known about this topic? Previous studies found higher rates of anxiety and depression in clinical cohorts of patients with atopic dermatitis. What does this study add? This study found dramatically higher rates of anxiety and depression among adults with atopic dermatitis in the U.S. population, which was primarily driven by atopic dermatitis severity.Anxiety and depression often go undiagnosed in adults with atopic dermatitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The most prominent symptoms of AD is itch, and separate measurement of change in itch severity will be extracted as a secondary outcome where available. The Dermatology Life Quality Index is the most commonly used instrument for quality of life in RCTs26; therefore, despite inadequate evidence for strong measurement properties, it will be prioritised in our analysis 26…”

Section: Methods and Analysismentioning

confidence: 99%

Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis

Drucker¹,

Ellis

Jabbar‐Lopez

et al. 2018

BMJ Open

View full text Add to dashboard Cite

IntroductionThere are numerous new systemic treatments for atopic dermatitis in various stages of development and most are being compared with placebo rather than active comparators. In order to understand the relative efficacy and safety of existing and new treatments for atopic dermatitis, robust mixed comparisons (ie, direct and indirect) would be beneficial. To address this gap, this protocol describes methods for a systematic review and network meta-analysis of systemic treatments for atopic dermatitis.Methods and analysisWe will update the search of a previous systematic review, including searches of the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, Latin American and Caribbean Health Science Information database and the Global Resource of EczemA Trials database in addition to clinical trial protocol registries. Title, abstract and full paper screening as well as data extraction will be conducted in duplicate by independent researchers. Primary outcomes include efficacy with regards to clinician-reported signs and patient-reported symptoms and safety with regards to withdrawal from treatment due to adverse events and the occurrence of serious adverse events. Secondary outcomes will include change in quality of life and itch severity. Where possible and appropriate, network meta-analysis will be performed for each outcome using a random-effects model within a Bayesian framework. If appropriate, the review will be transitioned to a living review with continuous updating of the analysis.Ethics and disseminationDissemination in a peer-reviewed scientific journal is planned.PROSPERO registration numberCRD42018088112; Pre-results.

show abstract

“…An Arabic version and a Ukrainian version have been published. The DFI has been used in many studies . A review of the use of the instrument showed that 26 studies correlated the DFI to other instruments, demonstrating its convergent validity.…”

Section: Resultsmentioning

confidence: 99%

Measuring the impact of dermatological conditions on family and caregivers: a review of dermatology‐specific instruments

Sampogna

Finlay

Salek

et al. 2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

The patient is the centre of a web of relationships and the impact of his/her disease on family members and caregivers must be taken into account. The aim of this study was to identify the specific instruments that measure the impact of a dermatological disease on the quality of life (QoL) of family members, by performing a systematic search of the literature. Fifteen papers were identified, describing the creation and validation of nine instruments. Four of them concerned atopic dermatitis (Dermatitis Family Index, DFI; Parents' Index QoL Atopic

show abstract

Eczema Trials: Quality of Life Instruments Used and Their Relation to Patient-reported Outcomes. A Systematic Review

Cited by 30 publications

References 205 publications

Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults

Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults

Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis

Measuring the impact of dermatological conditions on family and caregivers: a review of dermatology‐specific instruments

Contact Info

Product

Resources

About